AlphAIAlphAI — Financial news for AI agents
investing.comSEP 242 min read$CTNM

Goldman Sachs initiates coverage on Contineum Therapeutics stock

Goldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.

Original reporting
investing.com
Published Sep 24, 2026, 10:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CTNM
Bearish
medium confidence
Mentioned
$CTNM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CTNMBearishMed
01

Why it matters

Analyst coverage can move the stock; trial failure adds negative pressure.

02

Market read

New coverage and trial outcome constitute primary news for CTNM, influencing biotech sector sentiment.

03

What to watch

Potential off-label use of PIPE-791 for chronic pain not yet priced in.

Relevance 7/10Novelty 6/10Timing: today

Background

Goldman Sachs coverage initiation and recent trial results provide fresh data on Contineum Therapeutics.

Company-level read

Ticker impact

$CTNMBearishMedium confidence
Context

Goldman Sachs initiated coverage on Contineum Therapeutics with an Early-Stage Biotech rating and reported a Phase 2 trial failure for PIPE-307/JNJ-5120.

Expected impact

potential near-term decline of 5-10%

Evidence & confidence

Coverage start signals increased visibility; negative trial data adds downside pressure.

Market effects

Sector

May affect sentiment toward early-stage biotech stocks.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Despite trial failure, the cash position and pipeline depth could support a rebound.

Key entities

  • company
    Contineum Therapeutics Inc.

    Clinical-stage biopharma developing oral small molecule therapies.

  • financial_institution
    Goldman Sachs

    Initiated coverage with Early-Stage Biotech rating.

Read at source← All news

Related articles

SEP 25
$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min
SEP 15
$CTNMMedAI 8/10

Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 — BigGo Finance

Contineum Therapeutics (CTNM) shares fell in after-hours trading after its depression drug candidate, licensed to Johnson & Johnson (JNJ), missed the primary efficacy endpoint in a Phase 2 trial. This is the second Phase 2 failure for the same molecule in less than a year. The company's focus shifts to its lung-disease program, PIPE-791. JNJ is evaluating the trial data, but no decision on further development has been made. Contineum shares declined 3.5% to $14.30 in after-hours trading, while J

finance.biggo.com2 min
SEP 15
$CTNMMed

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics (CTNM) shares fell 9.58% after its Phase 2 MOONLIGHT-1 trial for depression drug JNJ-5120/PIPE-307, developed with Johnson & Johnson (JNJ), missed its primary efficacy endpoint. JNJ is reviewing data to determine next steps. CTNM's stock is near key support at $13.60 and resistance at $15.34.

aol.com2 min
SEP 14
$CTNMHighAI 8/10

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?

Contineum Therapeutics (CTNM) shares fell 10% after-hours after J&J's (JNJ) mid-stage trial of PIPE-307, licensed from CTNM, failed to meet its primary goal in treating major depressive disorder. This is the second mid-stage setback for the molecule in under a year. JNJ is reviewing exploratory measures and has not decided on further development. CTNM has $236.6 million in cash, expected to last through mid-2029.

newsable.asianetnews.com2 min
SEP 14
$CTNMHighAI 8/10

Contineum Therapeutics stock falls on phase 2 trial miss

Contineum Therapeutics (CTNM) shares dropped 8% after reporting its phase 2 trial for JNJ-5120/PIPE-307 in major depressive disorder failed to meet its primary endpoint. The drug was well-tolerated, and Johnson & Johnson is reviewing the data to determine next steps. Contineum Therapeutics is a clinical-stage biopharmaceutical company.

investing.com1 min